Tucatinib

Trade Name:

Tukysa

Manufacturer/Distributor:

Seattle Genetics Inc./Seagen Inc.

Canadian Importer: McKesson Specialty Distribution Inc.

Classification:

Antineoplastic agent

ATC Class:

L01EH03 - tucatinib

Status:

active

Notice of Compliance (yyyy/mm/dd):

2020/06/05

Date Marketed in Canada (yyyy/mm/dd):

2020/10/08

Presentation:

Tablet: 50 mg. DIN: 02499827

Tablet: 150 mg. DIN: 02499835

Comments:

Used in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Back to:

Drug Product Listings

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

British Columbia Drug and Poison Information Centre (BC DPIC)

Poison Information

Drug Information

Tucatinib

Follow DPIC